| Fiscal Year End | Company Status | Exempt Flag |
| November 30 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 26/Jan/2012 | 23/May/2023 | Canada | Alberta | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Biotechnology/Biopharmaceutical
| News Release December 14, 2014-BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. BioMmune is developing three technologies discovered at The University of British Columbia. They include, discovery of compounds that will be active in restoring immune-recognition of cancer cells resulting in the body's immune system to fight the cancer cells. A discovery relating to Channels, whose activities regulate activity of cells involved in the immune system to improve their ability to combat cancers, infections and also autoimmunities. Furthermore, the company is pursuing the modulation of CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases.
|
|
| *Capital Pool Company
| Seeking QT primarily in this sector: Technology
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *PAS | *Pascal Biosciences Inc. | TSX Venture | DELIST |
| *IMU | *Biommune Technologies Inc. | TSX Venture | DELIST |
| *MCT.P | *MC Partners Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Pascal Biosciences Inc. | 31/Mar/2017 | 23/May/2023 |
| *bioMmune Technologies Inc. | 29/May/2013 | 30/Mar/2017 |
| *MC Partners Inc. | 12/Sep/2011 | 28/May/2013 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
